Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107432 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
A Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT00107432: Completed Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, sponsored by National Cancer Institute (NCI).
NCT00107432 is a Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107432, a Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Primary Outcome
The frequency of best response to the new treatment will be tabulated and the exact 95% binomial confidence intervals will be computed.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG sorafenib tosylate
Study Locations (2)
Illinois
- Cancer and Leukemia Group B - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-10 |
| Phase | Phase 2 |
What the finished NCT00107432 record still lists
NCT00107432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 8 conditions, with Recurrent Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00107432 reports a single indexed study location in Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00107432 about?
NCT00107432 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.". This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00107432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2004-10.
What conditions does trial NCT00107432 study?
This clinical trial studies the following conditions: Recurrent Malignant Mesothelioma, Epithelial Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma.
What interventions are being tested in trial NCT00107432?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00107432?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107432 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00107432's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia